Role of adipose tissue in haemostasis, coagulation and fibrinolysis
Obesity is associated with an increased incidence of insulin resistance (IR), type 2 diabetes mellitus and cardiovascular diseases. The increased risk for cardiovascular diseases could partly be caused by a prothrombotic state that exists because of abdominal obesity. Adipose tissue induces thromboc...
Uloženo v:
| Vydáno v: | Obesity reviews Ročník 10; číslo 5; s. 554 - 563 |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
Oxford, UK
Oxford, UK : Blackwell Publishing Ltd
01.09.2009
Blackwell Publishing Ltd |
| Témata: | |
| ISSN: | 1467-7881, 1467-789X, 1467-789X |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Obesity is associated with an increased incidence of insulin resistance (IR), type 2 diabetes mellitus and cardiovascular diseases. The increased risk for cardiovascular diseases could partly be caused by a prothrombotic state that exists because of abdominal obesity. Adipose tissue induces thrombocyte activation by the production of adipose tissue-derived hormones, often called adipokines, of which some such as leptin and adiponectin have been shown to directly interfere with platelet function. Increased adipose tissue mass induces IR and systemic low-grade inflammation, also affecting platelet function. It has been demonstrated that adipose tissue directly impairs fibrinolysis by the production of plasminogen activator inhibitor-1 and possibly thrombin-activatable fibrinolysis inhibitor. Adipose tissue may contribute to enhanced coagulation by direct tissue factor production, but hypercoagulability is likely to be primarily caused by affecting hepatic synthesis of the coagulation factors fibrinogen, factor VII, factor VIII and tissue factor, by releasing free fatty acids and pro-inflammatory cytokines (tumour necrosis factor-α, interleukin-1β and interleukin-6) into the portal circulation and by inducing hepatic IR. Adipose tissue dysfunction could thus play a causal role in the prothrombotic state observed in obesity, by directly and indirectly affecting haemostasis, coagulation and fibrinolysis. |
|---|---|
| AbstractList | Summary
Obesity is associated with an increased incidence of insulin resistance (IR), type 2 diabetes mellitus and cardiovascular diseases. The increased risk for cardiovascular diseases could partly be caused by a prothrombotic state that exists because of abdominal obesity.
Adipose tissue induces thrombocyte activation by the production of adipose tissue‐derived hormones, often called adipokines, of which some such as leptin and adiponectin have been shown to directly interfere with platelet function. Increased adipose tissue mass induces IR and systemic low‐grade inflammation, also affecting platelet function. It has been demonstrated that adipose tissue directly impairs fibrinolysis by the production of plasminogen activator inhibitor‐1 and possibly thrombin‐activatable fibrinolysis inhibitor. Adipose tissue may contribute to enhanced coagulation by direct tissue factor production, but hypercoagulability is likely to be primarily caused by affecting hepatic synthesis of the coagulation factors fibrinogen, factor VII, factor VIII and tissue factor, by releasing free fatty acids and pro‐inflammatory cytokines (tumour necrosis factor‐α, interleukin‐1β and interleukin‐6) into the portal circulation and by inducing hepatic IR.
Adipose tissue dysfunction could thus play a causal role in the prothrombotic state observed in obesity, by directly and indirectly affecting haemostasis, coagulation and fibrinolysis. SummaryObesity is associated with an increased incidence of insulin resistance (IR), type 2 diabetes mellitus and cardiovascular diseases. The increased risk for cardiovascular diseases could partly be caused by a prothrombotic state that exists because of abdominal obesity.Adipose tissue induces thrombocyte activation by the production of adipose tissue-derived hormones, often called adipokines, of which some such as leptin and adiponectin have been shown to directly interfere with platelet function. Increased adipose tissue mass induces IR and systemic low-grade inflammation, also affecting platelet function. It has been demonstrated that adipose tissue directly impairs fibrinolysis by the production of plasminogen activator inhibitor-1 and possibly thrombin-activatable fibrinolysis inhibitor. Adipose tissue may contribute to enhanced coagulation by direct tissue factor production, but hypercoagulability is likely to be primarily caused by affecting hepatic synthesis of the coagulation factors fibrinogen, factor VII, factor VIII and tissue factor, by releasing free fatty acids and pro-inflammatory cytokines (tumour necrosis factor- alpha , interleukin-1 beta and interleukin-6) into the portal circulation and by inducing hepatic IR.Adipose tissue dysfunction could thus play a causal role in the prothrombotic state observed in obesity, by directly and indirectly affecting haemostasis, coagulation and fibrinolysis. Obesity is associated with an increased incidence of insulin resistance (IR), type 2 diabetes mellitus and cardiovascular diseases. The increased risk for cardiovascular diseases could partly be caused by a prothrombotic state that exists because of abdominal obesity. Adipose tissue induces thrombocyte activation by the production of adipose tissue‐derived hormones, often called adipokines, of which some such as leptin and adiponectin have been shown to directly interfere with platelet function. Increased adipose tissue mass induces IR and systemic low‐grade inflammation, also affecting platelet function. It has been demonstrated that adipose tissue directly impairs fibrinolysis by the production of plasminogen activator inhibitor‐1 and possibly thrombin‐activatable fibrinolysis inhibitor. Adipose tissue may contribute to enhanced coagulation by direct tissue factor production, but hypercoagulability is likely to be primarily caused by affecting hepatic synthesis of the coagulation factors fibrinogen, factor VII, factor VIII and tissue factor, by releasing free fatty acids and pro‐inflammatory cytokines (tumour necrosis factor‐α, interleukin‐1β and interleukin‐6) into the portal circulation and by inducing hepatic IR. Adipose tissue dysfunction could thus play a causal role in the prothrombotic state observed in obesity, by directly and indirectly affecting haemostasis, coagulation and fibrinolysis. Obesity is associated with an increased incidence of insulin resistance (IR), type 2 diabetes mellitus and cardiovascular diseases. The increased risk for cardiovascular diseases could partly be caused by a prothrombotic state that exists because of abdominal obesity. Adipose tissue induces thrombocyte activation by the production of adipose tissue-derived hormones, often called adipokines, of which some such as leptin and adiponectin have been shown to directly interfere with platelet function. Increased adipose tissue mass induces IR and systemic low-grade inflammation, also affecting platelet function. It has been demonstrated that adipose tissue directly impairs fibrinolysis by the production of plasminogen activator inhibitor-1 and possibly thrombin-activatable fibrinolysis inhibitor. Adipose tissue may contribute to enhanced coagulation by direct tissue factor production, but hypercoagulability is likely to be primarily caused by affecting hepatic synthesis of the coagulation factors fibrinogen, factor VII, factor VIII and tissue factor, by releasing free fatty acids and pro-inflammatory cytokines (tumour necrosis factor-α, interleukin-1β and interleukin-6) into the portal circulation and by inducing hepatic IR. Adipose tissue dysfunction could thus play a causal role in the prothrombotic state observed in obesity, by directly and indirectly affecting haemostasis, coagulation and fibrinolysis. Obesity is associated with an increased incidence of insulin resistance (IR), type 2 diabetes mellitus and cardiovascular diseases. The increased risk for cardiovascular diseases could partly be caused by a prothrombotic state that exists because of abdominal obesity. Adipose tissue induces thrombocyte activation by the production of adipose tissue-derived hormones, often called adipokines, of which some such as leptin and adiponectin have been shown to directly interfere with platelet function. Increased adipose tissue mass induces IR and systemic low-grade inflammation, also affecting platelet function. It has been demonstrated that adipose tissue directly impairs fibrinolysis by the production of plasminogen activator inhibitor-1 and possibly thrombin-activatable fibrinolysis inhibitor. Adipose tissue may contribute to enhanced coagulation by direct tissue factor production, but hypercoagulability is likely to be primarily caused by affecting hepatic synthesis of the coagulation factors fibrinogen, factor VII, factor VIII and tissue factor, by releasing free fatty acids and pro-inflammatory cytokines (tumour necrosis factor-alpha, interleukin-1beta and interleukin-6) into the portal circulation and by inducing hepatic IR. Adipose tissue dysfunction could thus play a causal role in the prothrombotic state observed in obesity, by directly and indirectly affecting haemostasis, coagulation and fibrinolysis.Obesity is associated with an increased incidence of insulin resistance (IR), type 2 diabetes mellitus and cardiovascular diseases. The increased risk for cardiovascular diseases could partly be caused by a prothrombotic state that exists because of abdominal obesity. Adipose tissue induces thrombocyte activation by the production of adipose tissue-derived hormones, often called adipokines, of which some such as leptin and adiponectin have been shown to directly interfere with platelet function. Increased adipose tissue mass induces IR and systemic low-grade inflammation, also affecting platelet function. It has been demonstrated that adipose tissue directly impairs fibrinolysis by the production of plasminogen activator inhibitor-1 and possibly thrombin-activatable fibrinolysis inhibitor. Adipose tissue may contribute to enhanced coagulation by direct tissue factor production, but hypercoagulability is likely to be primarily caused by affecting hepatic synthesis of the coagulation factors fibrinogen, factor VII, factor VIII and tissue factor, by releasing free fatty acids and pro-inflammatory cytokines (tumour necrosis factor-alpha, interleukin-1beta and interleukin-6) into the portal circulation and by inducing hepatic IR. Adipose tissue dysfunction could thus play a causal role in the prothrombotic state observed in obesity, by directly and indirectly affecting haemostasis, coagulation and fibrinolysis. Obesity is associated with an increased incidence of insulin resistance (IR), type 2 diabetes mellitus and cardiovascular diseases. The increased risk for cardiovascular diseases could partly be caused by a prothrombotic state that exists because of abdominal obesity. Adipose tissue induces thrombocyte activation by the production of adipose tissue-derived hormones, often called adipokines, of which some such as leptin and adiponectin have been shown to directly interfere with platelet function. Increased adipose tissue mass induces IR and systemic low-grade inflammation, also affecting platelet function. It has been demonstrated that adipose tissue directly impairs fibrinolysis by the production of plasminogen activator inhibitor-1 and possibly thrombin-activatable fibrinolysis inhibitor. Adipose tissue may contribute to enhanced coagulation by direct tissue factor production, but hypercoagulability is likely to be primarily caused by affecting hepatic synthesis of the coagulation factors fibrinogen, factor VII, factor VIII and tissue factor, by releasing free fatty acids and pro-inflammatory cytokines (tumour necrosis factor-alpha, interleukin-1beta and interleukin-6) into the portal circulation and by inducing hepatic IR. Adipose tissue dysfunction could thus play a causal role in the prothrombotic state observed in obesity, by directly and indirectly affecting haemostasis, coagulation and fibrinolysis. |
| Author | Visseren, F. L. J. Faber, D. R. De Groot, Ph. G. |
| Author_xml | – sequence: 1 fullname: Faber, D.R – sequence: 2 fullname: de Groot, Ph.G – sequence: 3 fullname: Visseren, F.L.J |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/19460118$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkk9v1DAQxS3Uiv7jK0BOcCHBjhM7llAlWNEWqaJSuxW9jbzJuHjJxoudiN1vj9OUPXCg9cEeaX5vRnrPR2Svcx0SkjCasXg-LDNWCJnKSt1lOaUqo7RUPNu8IIe7xt6urtgBOQphSSmTirOX5ICpQlDGqkMyu3YtJs4kurFrFzDpbQgDJrZLfmhcudDrYMP7pHb6fmh1b12X6K5JjF1427l2G7snZN_oNuCrx_eY3J59mc8u0sur86-zT5dpXZaSp3yhcCE4Ew2XwpRY89KYhnItEFHRRuYNSoE5NpUQVVWwwsjcNLKshDZSFfyYvJvmrr37NWDoYWVDjW2rO3RDAMkLmlNWjuTb_5KF4FLJeD8F5ozK6KKK4OtHcFissIG1tyvtt_DXyQicTkDtXQgeDdS2f_Cr99q2wCiM0cESxlRgTAjG6OAhOtjEAdU_A3Y7npZ-nKS_bYvbZ-vg6vN1LKI8neQ29LjZybX_CUJyWcL3b-dwI-Znc1ndwejum4k32oG-9zbA7U00nlMmJIv_jf8B2_TIVw |
| CitedBy_id | crossref_primary_10_1161_ATVBAHA_110_211946 crossref_primary_10_1111_ans_17679 crossref_primary_10_1159_000514614 crossref_primary_10_1016_j_phrs_2019_04_013 crossref_primary_10_1038_s41598_023_41186_2 crossref_primary_10_1016_j_bbrc_2009_12_158 crossref_primary_10_1016_j_thromres_2011_03_005 crossref_primary_10_2147_PLMI_S328891 crossref_primary_10_1007_s00464_013_3203_1 crossref_primary_10_1038_oby_2011_287 crossref_primary_10_1111_ajo_13141 crossref_primary_10_1038_nutd_2012_25 crossref_primary_10_1007_s00068_025_02922_7 crossref_primary_10_1007_s11239_012_0844_1 crossref_primary_10_1308_205016815814954911 crossref_primary_10_5482_HAMO_13_07_0034 crossref_primary_10_1016_j_rpth_2024_102392 crossref_primary_10_1111_jsr_12871 crossref_primary_10_1055_s_0041_1736166 crossref_primary_10_1080_00365513_2020_1731848 crossref_primary_10_1371_journal_pone_0168878 crossref_primary_10_1002_cdt3_154 crossref_primary_10_1159_000449028 crossref_primary_10_1007_s11239_017_1535_8 crossref_primary_10_1016_j_jvs_2011_01_003 crossref_primary_10_2337_db11_0828 crossref_primary_10_1016_j_atherosclerosis_2010_04_029 crossref_primary_10_1097_HS9_0000000000000457 crossref_primary_10_1055_s_0043_1772212 crossref_primary_10_1177_1076029613486016 crossref_primary_10_1016_j_atherosclerosis_2011_07_107 crossref_primary_10_2147_JAA_S318017 crossref_primary_10_1177_1076029621996445 crossref_primary_10_1371_journal_pone_0139549 crossref_primary_10_1007_s11886_014_0485_4 crossref_primary_10_1016_j_smrv_2019_101233 crossref_primary_10_1002_edm2_70021 crossref_primary_10_3389_fimmu_2020_576818 crossref_primary_10_1016_j_cca_2010_06_019 crossref_primary_10_1111_hae_12182 crossref_primary_10_1182_blood_2013_05_427708 crossref_primary_10_1111_jvim_16421 crossref_primary_10_1038_ijo_2014_208 crossref_primary_10_1016_j_numecd_2014_04_008 crossref_primary_10_1080_13813455_2020_1808996 crossref_primary_10_1016_j_chest_2016_07_011 crossref_primary_10_1089_jmf_2014_3307 crossref_primary_10_1097_PRS_0000000000011942 crossref_primary_10_3389_fphar_2021_706363 crossref_primary_10_1111_aos_16681 crossref_primary_10_1160_TH13_03_0212 crossref_primary_10_1016_j_thromres_2015_05_033 crossref_primary_10_1016_j_numecd_2017_02_007 crossref_primary_10_1097_MCA_0000000000000921 crossref_primary_10_1160_THS10_11_0739 crossref_primary_10_1007_s11739_011_0522_x crossref_primary_10_5494_wjh_v2_i1_13 crossref_primary_10_1097_SAP_0000000000004365 crossref_primary_10_1016_j_blre_2014_12_005 crossref_primary_10_1016_j_clinre_2016_11_002 crossref_primary_10_1016_j_numecd_2022_12_011 crossref_primary_10_1016_j_sxmr_2017_03_006 crossref_primary_10_1111_jth_13369 crossref_primary_10_1212_WNL_0000000000209431 crossref_primary_10_1186_1471_2164_14_557 crossref_primary_10_1194_jlr_M003988 crossref_primary_10_1177_0003319713520463 crossref_primary_10_1016_j_bjps_2020_08_105 crossref_primary_10_1097_HJH_0b013e3283388871 crossref_primary_10_1134_S2079057015040128 crossref_primary_10_4061_2011_781035 crossref_primary_10_1007_s00018_022_04234_0 crossref_primary_10_1111_j_1365_2141_2012_09160_x crossref_primary_10_1016_j_thromres_2016_06_012 crossref_primary_10_1097_FJC_0000000000001288 crossref_primary_10_1111_j_1549_8719_2009_00015_x crossref_primary_10_1038_s41598_023_45077_4 crossref_primary_10_1002_phar_1775 crossref_primary_10_1016_j_mce_2012_07_001 crossref_primary_10_1016_j_medcle_2020_06_025 crossref_primary_10_1038_oby_2011_361 crossref_primary_10_1186_s12864_017_4035_5 crossref_primary_10_1016_j_jss_2023_07_048 crossref_primary_10_1089_ars_2010_3848 crossref_primary_10_1016_j_jprot_2014_05_027 crossref_primary_10_3389_fmed_2023_1285898 crossref_primary_10_1016_j_thromres_2014_06_008 crossref_primary_10_1186_1472_6793_10_21 crossref_primary_10_1002_jbt_23342 crossref_primary_10_1111_j_1467_789X_2009_00700_x crossref_primary_10_1016_j_thromres_2010_06_002 crossref_primary_10_1186_s12933_023_01940_2 crossref_primary_10_1093_eurheartj_sus002 crossref_primary_10_1111_j_1538_7836_2012_04828_x crossref_primary_10_1038_s41598_024_76716_z crossref_primary_10_1002_smll_201602925 crossref_primary_10_1016_j_nutres_2017_03_001 crossref_primary_10_1097_MBC_0000000000000713 crossref_primary_10_1016_j_medcli_2020_06_014 crossref_primary_10_1038_ijo_2011_214 crossref_primary_10_1016_j_abb_2013_06_020 crossref_primary_10_1016_j_thromres_2018_08_007 crossref_primary_10_1530_REP_10_0074 crossref_primary_10_1161_ATVBAHA_113_302700 crossref_primary_10_1016_j_bpobgyn_2023_102407 crossref_primary_10_1111_joim_13044 crossref_primary_10_1155_2020_6145604 crossref_primary_10_1160_TH11_12_0864 crossref_primary_10_1258_vasc_2011_201201 crossref_primary_10_3390_life14010093 crossref_primary_10_1111_j_1467_789X_2010_00807_x crossref_primary_10_1111_j_1538_7836_2011_04285_x crossref_primary_10_1002_oby_23245 crossref_primary_10_1177_8755122515617200 crossref_primary_10_1016_j_molimm_2014_06_031 crossref_primary_10_3390_jcm10173879 crossref_primary_10_1017_S0007114514000890 crossref_primary_10_33590_emj_10312589 crossref_primary_10_1016_j_atherosclerosis_2015_01_033 crossref_primary_10_1080_13813455_2017_1369999 crossref_primary_10_1586_erc_10_160 crossref_primary_10_1097_TA_0000000000000490 crossref_primary_10_1016_j_thromres_2012_07_012 crossref_primary_10_1016_j_nutres_2015_10_011 crossref_primary_10_1016_j_soard_2018_12_014 crossref_primary_10_1038_nrcardio_2011_91 crossref_primary_10_1080_13813455_2018_1437749 crossref_primary_10_1017_S0007114511006027 crossref_primary_10_1089_met_2012_0077 crossref_primary_10_1007_s00104_011_2106_8 |
| Cites_doi | 10.1161/01.ATV.20.6.1682 10.1016/j.thromres.2007.06.002 10.1055/s-0037-1613999 10.1161/01.ATV.20.12.2511 10.1016/0021-9150(89)90104-4 10.1161/01.CIR.0000050621.67499.7D 10.1016/j.metabol.2004.08.016 10.1055/s-2003-39078 10.1007/s00424-007-0301-8 10.1038/oby.2006.277 10.1172/JCI29069 10.1002/hep.22350 10.1126/science.7624778 10.2337/diabetes.55.04.06.db05-1414 10.1016/j.bbrc.2006.01.004 10.1038/nm1166 10.1097/00019501-199611000-00004 10.1172/JCI118404 10.2337/diabetes.37.6.780 10.1016/j.febslet.2007.07.076 10.2337/db06-1656 10.1055/s-0037-1613566 10.1001/archinte.168.15.1678 10.1210/jc.2007-0933 10.1161/01.ATV.18.1.1 10.2337/db06-0911 10.1016/j.atherosclerosis.2005.10.034 10.1023/A:1013908332232 10.1038/oby.2003.131 10.1016/S1056-8727(01)00196-9 10.1053/j.gastro.2007.03.052 10.1007/s00125-006-0173-z 10.1182/blood.V98.12.3353 10.1160/TH07-10-0589 10.2337/diabetes.55.01.06.db05-1026 10.1111/j.1538-7836.2008.02982.x 10.1111/j.1538-7836.2008.02988.x 10.1172/JCI115440 10.1073/pnas.95.13.7591 10.4049/jimmunol.165.2.1053 10.1038/nm841 10.1016/0168-8278(90)90223-E 10.1007/BF03402048 10.1161/01.ATV.0000194076.84568.81 10.1136/jcp.44.2.139 10.1016/S0140-6736(05)67663-5 10.1016/j.ejphar.2006.11.052 10.2337/db06-0133 10.1182/blood-2002-09-2944 10.1073/pnas.96.12.6902 10.1172/JCI13143 10.1111/j.1538-7836.2007.02578.x 10.1160/TH07-03-0213 10.1016/j.bbrc.2006.04.173 10.3748/wjg.v7.i5.710 10.1161/01.ATV.0000146531.79402.9a 10.2337/db06-1405 10.1056/NEJMra071014 10.1161/hc5001.101061 10.1016/j.diabres.2005.12.008 10.1210/jcem.87.2.8214 10.2337/diabetes.48.2.426 10.1001/archinte.158.22.2485 10.1002/hep.22404 10.1046/j.1538-7836.2003.00147.x 10.1161/01.ATV.0000077401.36885.BB 10.1007/s001250050868 10.1055/s-0038-1650524 |
| ContentType | Journal Article |
| Copyright | 2009 The Authors. Journal compilation © 2009 International Association for the Study of Obesity |
| Copyright_xml | – notice: 2009 The Authors. Journal compilation © 2009 International Association for the Study of Obesity |
| DBID | FBQ BSCLL AAYXX CITATION CGR CUY CVF ECM EIF NPM 7U1 C1K 7S9 L.6 7X8 |
| DOI | 10.1111/j.1467-789X.2009.00593.x |
| DatabaseName | AGRIS Istex CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Risk Abstracts Environmental Sciences and Pollution Management AGRICOLA AGRICOLA - Academic MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Risk Abstracts Environmental Sciences and Pollution Management AGRICOLA AGRICOLA - Academic MEDLINE - Academic |
| DatabaseTitleList | Risk Abstracts CrossRef AGRICOLA MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1467-789X |
| EndPage | 563 |
| ExternalDocumentID | 19460118 10_1111_j_1467_789X_2009_00593_x OBR593 ark_67375_WNG_S6TFT78X_4 US201301671788 |
| Genre | reviewArticle Research Support, Non-U.S. Gov't Journal Article Review |
| GroupedDBID | --- .3N .GA .Y3 05W 0R~ 10A 123 1OC 29N 31~ 33P 36B 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5HH 5LA 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AANLZ AAONW AASGY AAVGM AAXRX AAZKR ABCQN ABCUV ABEML ABHUG ABJNI ABPTK ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFS ACGOF ACMXC ACPOU ACPRK ACSCC ACXBN ACXME ACXQS ADAWD ADBBV ADBTR ADDAD ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFFPM AFGKR AFPWT AFRAH AFVGU AFZJQ AGJLS AHMBA AIACR AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EBS EJD ESX EX3 F00 F01 F04 F5P FBQ FEDTE FUBAC G-S G.N GODZA H.X HF~ HVGLF HZI HZ~ IHE IX1 J0M K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OVD P2P P2W P2X P2Z P4B P4D PQQKQ Q.N Q11 QB0 R.K ROL RX1 SUPJJ TEORI UB1 W8V W99 WBKPD WHWMO WIH WIJ WIK WOHZO WOW WQJ WRC WVDHM WXI WXSBR XG1 YFH ZZTAW ~IA ~KM ~WT AAHBH AAHQN AAIPD AAMMB AAMNL AANHP AAYCA ACRPL ACYXJ ADNMO AEFGJ AEYWJ AFWVQ AGHNM AGQPQ AGXDD AGYGG AHBTC AIDQK AIDYY AITYG ALVPJ BSCLL HGLYW OIG AAYXX CITATION O8X CGR CUY CVF ECM EIF NPM 7U1 C1K 7S9 L.6 7X8 |
| ID | FETCH-LOGICAL-c5573-3b9eb6316d376f5ec35ffd03a6eee90d72de76e2ed86688414f72fd7586af7943 |
| IEDL.DBID | DRFUL |
| ISICitedReferencesCount | 149 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000269387400005&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1467-7881 1467-789X |
| IngestDate | Sun Nov 09 13:22:00 EST 2025 Fri Jul 11 07:25:50 EDT 2025 Tue Oct 07 09:38:07 EDT 2025 Wed Feb 19 01:49:48 EST 2025 Tue Nov 18 22:02:26 EST 2025 Sat Nov 29 03:04:32 EST 2025 Tue Sep 09 05:10:19 EDT 2025 Sun Sep 21 06:19:06 EDT 2025 Wed Dec 27 19:07:23 EST 2023 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 5 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c5573-3b9eb6316d376f5ec35ffd03a6eee90d72de76e2ed86688414f72fd7586af7943 |
| Notes | http://dx.doi.org/10.1111/j.1467-789X.2009.00593.x istex:428E11000B045DA03454357BDDF6E6A8D2BBDAA9 ark:/67375/WNG-S6TFT78X-4 ArticleID:OBR593 ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Article-1 ObjectType-Feature-2 ObjectType-Review-3 |
| PMID | 19460118 |
| PQID | 21071469 |
| PQPubID | 23462 |
| PageCount | 10 |
| ParticipantIDs | proquest_miscellaneous_734020154 proquest_miscellaneous_46379746 proquest_miscellaneous_21071469 pubmed_primary_19460118 crossref_citationtrail_10_1111_j_1467_789X_2009_00593_x crossref_primary_10_1111_j_1467_789X_2009_00593_x wiley_primary_10_1111_j_1467_789X_2009_00593_x_OBR593 istex_primary_ark_67375_WNG_S6TFT78X_4 fao_agris_US201301671788 |
| PublicationCentury | 2000 |
| PublicationDate | September 2009 |
| PublicationDateYYYYMMDD | 2009-09-01 |
| PublicationDate_xml | – month: 09 year: 2009 text: September 2009 |
| PublicationDecade | 2000 |
| PublicationPlace | Oxford, UK |
| PublicationPlace_xml | – name: Oxford, UK – name: England |
| PublicationTitle | Obesity reviews |
| PublicationTitleAlternate | Obes Rev |
| PublicationYear | 2009 |
| Publisher | Oxford, UK : Blackwell Publishing Ltd Blackwell Publishing Ltd |
| Publisher_xml | – name: Oxford, UK : Blackwell Publishing Ltd – name: Blackwell Publishing Ltd |
| References | Eichinger S, Hron G, Bialonczyk C, Hirschl M, Minar E, Wagner O, Heinze G, Kyrle PA. Overweight, obesity, and the risk of recurrent venous thromboembolism. Arch Intern Med 2008; 168: 1678-1683. Hattori Y, Hattori S, Akimoto K, Nishikimi T, Suzuki K, Matsuoka H, Kasai K. Globular adiponectin activates nuclear factor-kappa B and activating protein-1 and enhances angiotensin II-induced proliferation in cardiac fibroblasts. Diabetes 2007; 56: 804-808. Wallace AM, McMahon AD, Packard CJ, Kelly A, Shepherd J, Gaw A, Sattar N. Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS). Circulation 2001; 104: 3052-3056. Wang Z, Lv J, Zhang R, Zhu Y, Zhu D, Sun Y, Zhu J, Han X. Co-culture with fat cells induces cellular insulin resistance in primary hepatocytes. Biochem Biophys Res Commun 2006; 345: 976-983. Konstantinides S, Schafer K, Koschnick S, Loskutoff DJ. Leptin-dependent platelet aggregation and arterial thrombosis suggests a mechanism for atherothrombotic disease in obesity. J Clin Invest 2001; 108: 1533-1540. Santos-Martinez MJ, Medina C, Jurasz P, Radomski MW. Role of metalloproteinases in platelet function. Thromb Res 2008; 121: 535-542. Koenig W. Fibrin(ogen) in cardiovascular disease: an update. Thromb Haemost 2003; 89: 601-609. Hosogai N, Fukuhara A, Oshima K, Miyata Y, Tanaka S, Segawa K, Furukawa S, Tochino Y, Komuro R, Matsuda M, Shimomura I. Adipose tissue hypoxia in obesity and its impact on adipocytokine dysregulation. Diabetes 2007; 56: 901-911. Cigolini M, Targher G, Agostino G, Tonoli M, Muggeo M, De SG. Liver steatosis and its relation to plasma haemostatic factors in apparently healthy men - role of the metabolic syndrome. Thromb Haemost 1996; 76: 69-73. Shoji T, Koyama H, Fukumoto S, Maeno T, Yokoyama H, Shinohara K, Emoto M, Shoji T, Yamane T, Hino M, Shioi A, Nishizawa Y. Platelet activation is associated with hypoadiponectinemia and carotid atherosclerosis. Atherosclerosis 2006; 188: 190-195. Cancello R, Tordjman J, Poitou C, Guilhem G, Bouillot JL, Hugol D, Coussieu C, Basdevant A, Bar HA, Bedossa P, Guerre-Millo M, Clement K. Increased infiltration of macrophages in omental adipose tissue is associated with marked hepatic lesions in morbid human obesity. Diabetes 2006; 55: 1554-1561. Lijnen HR. Matrix metalloproteinases and cellular fibrinolytic activity. Biochemistry (Mosc) 2002; 67: 92-98. Loskutoff DJ, Samad F. The adipocyte and hemostatic balance in obesity: studies of PAI-1. Arterioscler Thromb Vasc Biol 1998; 18: 1-6. Napoleone E, Di Santo A, Amore C, Baccante G, Di Febbo C, Porreca E, De Gaetano G, Donati MB, Lorenzet R. Leptin induces tissue factor expression in human peripheral blood mononuclear cells: a possible link between obesity and cardiovascular risk? J Thromb Haemost 2007; 5: 1462-1468. Ogden CL, Yanovski SZ, Carroll MD, Flegal KM. The epidemiology of obesity. Gastroenterology 2007; 132: 2087-2102. Yusuf S, Hawken S, Ounpuu S, Bautista L, Franzosi MG, Commerford P, Lang CC, Rumboldt Z, Onen CL, Lisheng L, Tanomsup S, Wangai P Jr., Razak F, Sharma AM, Anand SS. Obesity and the risk of myocardial infarction in 27 000 participants from 52 countries: a case-control study. Lancet 2005; 366: 1640-1649. Schneider DJ, Sobel BE. Synergistic augmentation of expression of plasminogen activator inhibitor type-1 induced by insulin, very-low-density lipoproteins, and fatty acids. Coron Artery Dis 1996; 7: 813-817. Campfield LA, Smith FJ, Guisez Y, Devos R, Burn P. Recombinant mouse OB protein: evidence for a peripheral signal linking adiposity and central neural networks. Science 1995; 269: 546-549. Bogdanov VY, Balasubramanian V, Hathcock J, Vele O, Lieb M, Nemerson Y. Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein. Nat Med 2003; 9: 458-462. Mosnier LO, Buijtenhuijs P, Marx PF, Meijers JC, Bouma BN. Identification of thrombin activatable fibrinolysis inhibitor (TAFI) in human platelets. Blood 2003; 101: 4844-4846. Simpson AJ, Booth NA, Moore NR, Bennett B. Distribution of plasminogen activator inhibitor (PAI-1) in tissues. J Clin Pathol 1991; 44: 139-143. Cai D, Yuan M, Frantz DF, Melendez PA, Hansen L, Lee J, Shoelson SE. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappa B. Nat Med 2005; 11: 183-190. Emanuele N, Azad N, Abraira C, Henderson W, Colwell J, Levin S, Nuttall F, Comstock J, Sawin C, Silbert C, Marcovina S, Lee HS. Effect of intensive glycemic control on fibrinogen, lipids, and lipoproteins: veterans affairs cooperative study in type II diabetes mellitus. Arch Intern Med 1998; 158: 2485-2490. Bergman RN, Kim SP, Catalano KJ, Hsu IR, Chiu JD, Kabir M, Hucking K, Ader M. Why visceral fat is bad: mechanisms of the metabolic syndrome. Obesity (Silver Spring) 2006; 14(Suppl. 1): 16S-19S. Trovati M, Anfossi G. Influence of insulin and of insulin resistance on platelet and vascular smooth muscle cell function. J Diabetes Complications 2002; 16: 35-40. Begbie M, Notley C, Tinlin S, Sawyer L, Lillicrap D. The factor VIII acute phase response requires the participation of NF-kappa B and C/EBP. Thromb Haemost 2000; 84: 216-222. Van Hul M, Lijnen HR. A functional role of gelatinase A in the development of nutritionally induced obesity in mice. J Thromb Haemost 2008; 6: 1198-1206. Busam KJ, Bauer TM, Bauer J, Gerok W, Decker K. Interleukin-6 release by rat liver macrophages. J Hepatol 1990; 11: 367-373. Wang B, Wood IS, Trayhurn P. Dysregulation of the expression and secretion of inflammation-related adipokines by hypoxia in human adipocytes. Pflugers Arch 2007; 455: 479-492. Konstantinides S, Schafer K, Neels JG, Dellas C, Loskutoff DJ. Inhibition of endogenous leptin protects mice from arterial and venous thrombosis. Arterioscler Thromb Vasc Biol 2004; 24: 2196-2201. Fain JN, Madan AK. Insulin enhances vascular endothelial growth factor, interleukin-8, and plasminogen activator inhibitor 1 but not interleukin-6 release by human adipocytes. Metabolism 2005; 54: 220-226. Van Der PD, Milner KL, Hui J, Hodge A, Trenell MI, Kench JG, London R, Peduto T, Chisholm DJ, George J. Visceral fat: a key mediator of steatohepatitis in metabolic liver disease. Hepatology 2008; 48: 449-457. Samad F, Pandey M, Bell PA, Loskutoff DJ. Insulin continues to induce plasminogen activator inhibitor 1 gene expression in insulin-resistant mice and adipocytes. Mol Med 2000; 6: 680-692. Laviola L, Perrini S, Cignarelli A, Natalicchio A, Leonardini A, De SF, Cuscito M, De FM, Memeo V, Neri V, Cignarelli M, Giorgino R, Giorgino F. Insulin signaling in human visceral and subcutaneous adipose tissue in vivo. Diabetes 2006; 55: 952-961. Kato H, Kashiwagi H, Shiraga M, Tadokoro S, Kamae T, Ujiie H, Honda S, Miyata S, Ijiri Y, Yamamoto J, Maeda N, Funahashi T, Kurata Y, Shimomura I, Tomiyama Y, Kanakura Y. Adiponectin acts as an endogenous antithrombotic factor. Arterioscler Thromb Vasc Biol 2006; 26: 224-230. Vaidyula VR, Rao AK, Mozzoli M, Homko C, Cheung P, Boden G. Effects of hyperglycemia and hyperinsulinemia on circulating tissue factor procoagulant activity and platelet CD40 ligand. Diabetes 2006; 55: 202-208. Curat CA, Wegner V, Sengenes C, Miranville A, Tonus C, Busse R, Bouloumie A. Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin. Diabetologia 2006; 49: 744-747. Chen B, Lam KS, Wang Y, Wu D, Lam MC, Shen J, Wong L, Hoo RL, Zhang J, Xu A. Hypoxia dysregulates the production of adiponectin and plasminogen activator inhibitor-1 independent of reactive oxygen species in adipocytes. Biochem Biophys Res Commun 2006; 341: 549-556. Sambola A, Osende J, Hathcock J, Degen M, Nemerson Y, Fuster V, Crandall J, Badimon JJ. Role of risk factors in the modulation of tissue factor activity and blood thrombogenicity. Circulation 2003; 107: 973-977. Alessi MC, Bastelica D, Mavri A, Morange P, Berthet B, Grino M, Juhan-Vague I. Plasma PAI-1 levels are more strongly related to liver steatosis than to adipose tissue accumulation. Arterioscler Thromb Vasc Biol 2003; 23: 1262-1268. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest 2006; 116: 1793-1801. Samad F, Yamamoto K, Loskutoff DJ. Distribution and regulation of plasminogen activator inhibitor-1 in murine adipose tissue in vivo. Induction by tumor necrosis factor-alpha and lipopolysaccharide. J Clin Invest 1996; 97: 37-46. Nakata M, Yada T, Soejima N, Maruyama I. Leptin promotes aggregation of human platelets via the long form of its receptor. Diabetes 1999; 48: 426-429. Dellas C, Schafer K, Rohm IK, Lankeit M, Leifheit M, Loskutoff DJ, Hasenfuss G, Konstantinides SV. Leptin signalling and leptin-mediated activation of human platelets: importance of JAK2 and the phospholipases Cgamma2 and A2. Thromb Haemost 2007; 98: 1063-1071. Hori Y, Nakatani K, Morioka K, Katsuki A, Gabazza EC, Yano Y, Nobori T, Adachi Y, Sumida Y. Insulin enhanced thrombin-activable fibrinolysis inhibitor expression through PI3 kinase/Akt pathway. Int J Mol Med 2005; 15: 265-268. Kopp CW, Kopp HP, Steiner S, Kriwanek S, Krzyzanowska K, Bartok A, Roka R, Minar E, Schernthaner G. Weight loss reduces tissue factor in morbidly obese patients. Obes Res 2003; 11: 950-956. Clement S, Juge-Aubry C, Sgroi A, Conzelmann S, Pazienza V, Pittet-Cuenod B, Meier CA, Negro F. Monocyte chemoattractant protein-1 secreted by adipose tissue induces direct lipid accumulation in hepatocytes. Hepatology 2008; 48: 799-807. Mitropoulos KA, Miller GJ, Reeves BE, Wilkes HC, Cruickshank JK. Factor VII coagulant activity is strongly associated with the plasma concentration of large lipoprotein particles in middle-aged men. Atherosclerosis 1989; 76: 203-208. Sato T, Miwa T, Akatsu H, Matsukawa N, Obata K, Okada N, Campbell W, Okada H.. Pro-carboxypeptidase R is an acute phase protein in the mouse, whereas carboxypeptidase N is not. J Immunol 2000; 165: 1053-1058. Samad F, Pandey M, Loskutoff DJ. Regulation of tissue factor gene expression 2002; 16 1990; 11 2006; 73 2000; 6 1988; 37 1999; 48 2007; 581 2004; 24 1992; 18 2008; 6 1998; 158 2001; 108 1998; 41 2001; 104 1996; 76 2003; 11 2007; 455 1998; 18 1989; 76 1991; 44 1991; 88 2007; 132 2002; 87 2006; 26 2003; 9 2007; 5 1999; 96 2000; 165 2003; 1 1998; 95 2001; 98 2003; 89 1996; 7 2006; 55 2006; 14 2000; 20 2003; 35 2007; 92 2008; 99 2008; 168 2006; 116 2007; 98 2008; 121 2007; 56 1996; 97 2007; 357 2007; 558 2003; 107 2001; 7 2005; 366 2006; 49 2002; 67 2000; 84 2008; 48 2006; 341 1995; 269 2005; 54 2005; 15 2003; 101 2005; 11 2006; 188 2006; 345 2003; 23 e_1_2_9_52_2 e_1_2_9_50_2 e_1_2_9_71_2 e_1_2_9_10_2 e_1_2_9_33_2 e_1_2_9_56_2 e_1_2_9_12_2 Christiaens V (e_1_2_9_57_2) 2008; 99 Scelles V (e_1_2_9_37_2) 1992; 18 Hori Y (e_1_2_9_54_2) 2005; 15 e_1_2_9_14_2 e_1_2_9_16_2 e_1_2_9_35_2 e_1_2_9_58_2 e_1_2_9_18_2 e_1_2_9_39_2 e_1_2_9_41_2 e_1_2_9_62_2 e_1_2_9_60_2 e_1_2_9_20_2 e_1_2_9_45_2 e_1_2_9_66_2 e_1_2_9_22_2 e_1_2_9_43_2 e_1_2_9_64_2 e_1_2_9_6_2 e_1_2_9_4_2 e_1_2_9_2_2 Cigolini M (e_1_2_9_70_2) 1996; 76 e_1_2_9_8_2 e_1_2_9_24_2 e_1_2_9_49_2 e_1_2_9_26_2 e_1_2_9_47_2 e_1_2_9_68_2 e_1_2_9_28_2 e_1_2_9_51_2 e_1_2_9_30_2 Begbie M (e_1_2_9_31_2) 2000; 84 e_1_2_9_34_2 e_1_2_9_55_2 e_1_2_9_11_2 e_1_2_9_32_2 e_1_2_9_53_2 e_1_2_9_13_2 e_1_2_9_38_2 e_1_2_9_59_2 e_1_2_9_15_2 e_1_2_9_36_2 e_1_2_9_17_2 e_1_2_9_19_2 e_1_2_9_40_2 e_1_2_9_63_2 e_1_2_9_61_2 e_1_2_9_21_2 e_1_2_9_44_2 e_1_2_9_67_2 e_1_2_9_23_2 e_1_2_9_42_2 e_1_2_9_65_2 e_1_2_9_7_2 e_1_2_9_5_2 e_1_2_9_3_2 e_1_2_9_9_2 e_1_2_9_25_2 e_1_2_9_48_2 e_1_2_9_27_2 e_1_2_9_46_2 e_1_2_9_69_2 e_1_2_9_29_2 |
| References_xml | – reference: Loskutoff DJ, Samad F. The adipocyte and hemostatic balance in obesity: studies of PAI-1. Arterioscler Thromb Vasc Biol 1998; 18: 1-6. – reference: Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest 2006; 116: 1793-1801. – reference: Eriksson P, Reynisdottir S, Lonnqvist F, Stemme V, Hamsten A, Arner P. Adipose tissue secretion of plasminogen activator inhibitor-1 in non-obese and obese individuals. Diabetologia 1998; 41: 65-71. – reference: Aubert H, Frere C, Aillaud MF, Morange PE, Juhan-Vague I, Alessi MC. Weak and non-independent association between plasma TAFI antigen levels and the insulin resistance syndrome. J Thromb Haemost 2003; 1: 791-797. – reference: Cai D, Yuan M, Frantz DF, Melendez PA, Hansen L, Lee J, Shoelson SE. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappa B. Nat Med 2005; 11: 183-190. – reference: Kopp CW, Kopp HP, Steiner S, Kriwanek S, Krzyzanowska K, Bartok A, Roka R, Minar E, Schernthaner G. Weight loss reduces tissue factor in morbidly obese patients. Obes Res 2003; 11: 950-956. – reference: Fain JN, Madan AK. Insulin enhances vascular endothelial growth factor, interleukin-8, and plasminogen activator inhibitor 1 but not interleukin-6 release by human adipocytes. Metabolism 2005; 54: 220-226. – reference: Campfield LA, Smith FJ, Guisez Y, Devos R, Burn P. Recombinant mouse OB protein: evidence for a peripheral signal linking adiposity and central neural networks. Science 1995; 269: 546-549. – reference: Sambola A, Osende J, Hathcock J, Degen M, Nemerson Y, Fuster V, Crandall J, Badimon JJ. Role of risk factors in the modulation of tissue factor activity and blood thrombogenicity. Circulation 2003; 107: 973-977. – reference: Boden G, Vaidyula VR, Homko C, Cheung P, Rao AK. Circulating tissue factor procoagulant activity and thrombin generation in patients with type 2 diabetes: effects of insulin and glucose. J Clin Endocrinol Metab 2007; 92: 4352-4358. – reference: Yusuf S, Hawken S, Ounpuu S, Bautista L, Franzosi MG, Commerford P, Lang CC, Rumboldt Z, Onen CL, Lisheng L, Tanomsup S, Wangai P Jr., Razak F, Sharma AM, Anand SS. Obesity and the risk of myocardial infarction in 27 000 participants from 52 countries: a case-control study. Lancet 2005; 366: 1640-1649. – reference: Laviola L, Perrini S, Cignarelli A, Natalicchio A, Leonardini A, De SF, Cuscito M, De FM, Memeo V, Neri V, Cignarelli M, Giorgino R, Giorgino F. Insulin signaling in human visceral and subcutaneous adipose tissue in vivo. Diabetes 2006; 55: 952-961. – reference: Mosnier LO, Buijtenhuijs P, Marx PF, Meijers JC, Bouma BN. Identification of thrombin activatable fibrinolysis inhibitor (TAFI) in human platelets. Blood 2003; 101: 4844-4846. – reference: Scelles V, Raccah D, Alessi MC, Vialle JM, Juhan-Vague I, Vague P. Plasminogen activator inhibitor 1 and insulin levels in various insulin resistance states. Diabete Metab 1992; 18: 38-42. – reference: Kitagawa N, Yano Y, Gabazza EC, Bruno NE, Araki R, Matsumoto K, Katsuki A, Hori Y, Nakatani K, Taguchi O, Sumida Y, Suzuki K, Adachi Y. Different metabolic correlations of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 in non-obese type 2 diabetic patients. Diabetes Res Clin Pract 2006; 73: 150-157. – reference: Bajzar L. Thrombin activatable fibrinolysis inhibitor and an antifibrinolytic pathway. Arterioscler Thromb Vasc Biol 2000; 20: 2511-2518. – reference: Eichinger S, Hron G, Bialonczyk C, Hirschl M, Minar E, Wagner O, Heinze G, Kyrle PA. Overweight, obesity, and the risk of recurrent venous thromboembolism. Arch Intern Med 2008; 168: 1678-1683. – reference: Hattori Y, Hattori S, Akimoto K, Nishikimi T, Suzuki K, Matsuoka H, Kasai K. Globular adiponectin activates nuclear factor-kappa B and activating protein-1 and enhances angiotensin II-induced proliferation in cardiac fibroblasts. Diabetes 2007; 56: 804-808. – reference: Lijnen HR. Matrix metalloproteinases and cellular fibrinolytic activity. Biochemistry (Mosc) 2002; 67: 92-98. – reference: Vaidyula VR, Rao AK, Mozzoli M, Homko C, Cheung P, Boden G. Effects of hyperglycemia and hyperinsulinemia on circulating tissue factor procoagulant activity and platelet CD40 ligand. Diabetes 2006; 55: 202-208. – reference: Koenig W. Fibrin(ogen) in cardiovascular disease: an update. Thromb Haemost 2003; 89: 601-609. – reference: Simpson AJ, Booth NA, Moore NR, Bennett B. Distribution of plasminogen activator inhibitor (PAI-1) in tissues. J Clin Pathol 1991; 44: 139-143. – reference: Birgel M, Gottschling-Zeller H, Rohrig K, Hauner H. Role of cytokines in the regulation of plasminogen activator inhibitor-1 expression and secretion in newly differentiated subcutaneous human adipocytes. Arterioscler Thromb Vasc Biol 2000; 20: 1682-1687. – reference: Wang B, Wood IS, Trayhurn P. Dysregulation of the expression and secretion of inflammation-related adipokines by hypoxia in human adipocytes. Pflugers Arch 2007; 455: 479-492. – reference: Alessi MC, Bastelica D, Mavri A, Morange P, Berthet B, Grino M, Juhan-Vague I. Plasma PAI-1 levels are more strongly related to liver steatosis than to adipose tissue accumulation. Arterioscler Thromb Vasc Biol 2003; 23: 1262-1268. – reference: Van Hul M, Lijnen HR. A functional role of gelatinase A in the development of nutritionally induced obesity in mice. J Thromb Haemost 2008; 6: 1198-1206. – reference: Curat CA, Wegner V, Sengenes C, Miranville A, Tonus C, Busse R, Bouloumie A. Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin. Diabetologia 2006; 49: 744-747. – reference: Mitropoulos KA, Miller GJ, Reeves BE, Wilkes HC, Cruickshank JK. Factor VII coagulant activity is strongly associated with the plasma concentration of large lipoprotein particles in middle-aged men. Atherosclerosis 1989; 76: 203-208. – reference: Sato T, Miwa T, Akatsu H, Matsukawa N, Obata K, Okada N, Campbell W, Okada H.. Pro-carboxypeptidase R is an acute phase protein in the mouse, whereas carboxypeptidase N is not. J Immunol 2000; 165: 1053-1058. – reference: Hori Y, Gabazza EC, Yano Y, Katsuki A, Suzuki K, Adachi Y, Sumida Y. Insulin resistance is associated with increased circulating level of thrombin-activatable fibrinolysis inhibitor in type 2 diabetic patients. J Clin Endocrinol Metab 2002; 87: 660-665. – reference: Elbatarny HS, Netherton SJ, Ovens JD, Ferguson AV, Maurice DH. Adiponectin, ghrelin, and leptin differentially influence human platelet and human vascular endothelial cell functions: implication in obesity-associated cardiovascular diseases. Eur J Pharmacol 2007; 558: 7-13. – reference: Riba R, Hughes CE, Graham A, Watson SP, Naseem KM. Globular adiponectin induces platelet activation through the collagen receptor GPVI-Fc receptor gamma chain complex. J Thromb Haemost 2008; 6: 1012-1020. – reference: Samad F, Pandey M, Loskutoff DJ. Tissue factor gene expression in the adipose tissues of obese mice. Proc Natl Acad Sci U S A 1998; 95: 7591-7596. – reference: Fan JG, Chen LH, Xu ZJ, Zeng MD. Overexpression of hepatic plasminogen activator inhibitor type 1 mRNA in rabbits with fatty liver. World J Gastroenterol 2001; 7: 710-712. – reference: Samad F, Yamamoto K, Loskutoff DJ. Distribution and regulation of plasminogen activator inhibitor-1 in murine adipose tissue in vivo. Induction by tumor necrosis factor-alpha and lipopolysaccharide. J Clin Invest 1996; 97: 37-46. – reference: He G, Pedersen SB, Bruun JM, Lihn AS, Jensen PF, Richelsen B. Differences in plasminogen activator inhibitor 1 in subcutaneous versus omental adipose tissue in non-obese and obese subjects. Horm Metab Res 2003; 35: 178-182. – reference: Samad F, Uysal KT, Wiesbrock SM, Pandey M, Hotamisligil GS, Loskutoff DJ. Tumor necrosis factor alpha is a key component in the obesity-linked elevation of plasminogen activator inhibitor 1. Proc Natl Acad Sci U S A 1999; 96: 6902-6907. – reference: Emanuele N, Azad N, Abraira C, Henderson W, Colwell J, Levin S, Nuttall F, Comstock J, Sawin C, Silbert C, Marcovina S, Lee HS. Effect of intensive glycemic control on fibrinogen, lipids, and lipoproteins: veterans affairs cooperative study in type II diabetes mellitus. Arch Intern Med 1998; 158: 2485-2490. – reference: Kato H, Kashiwagi H, Shiraga M, Tadokoro S, Kamae T, Ujiie H, Honda S, Miyata S, Ijiri Y, Yamamoto J, Maeda N, Funahashi T, Kurata Y, Shimomura I, Tomiyama Y, Kanakura Y. Adiponectin acts as an endogenous antithrombotic factor. Arterioscler Thromb Vasc Biol 2006; 26: 224-230. – reference: Bergman RN, Kim SP, Catalano KJ, Hsu IR, Chiu JD, Kabir M, Hucking K, Ader M. Why visceral fat is bad: mechanisms of the metabolic syndrome. Obesity (Silver Spring) 2006; 14(Suppl. 1): 16S-19S. – reference: Hosogai N, Fukuhara A, Oshima K, Miyata Y, Tanaka S, Segawa K, Furukawa S, Tochino Y, Komuro R, Matsuda M, Shimomura I. Adipose tissue hypoxia in obesity and its impact on adipocytokine dysregulation. Diabetes 2007; 56: 901-911. – reference: Christiaens V, Scroyen I, Lijnen HR. Role of proteolysis in development of murine adipose tissue. Thromb Haemost 2008; 99: 290-294. – reference: Begbie M, Notley C, Tinlin S, Sawyer L, Lillicrap D. The factor VIII acute phase response requires the participation of NF-kappa B and C/EBP. Thromb Haemost 2000; 84: 216-222. – reference: Trovati M, Anfossi G. Influence of insulin and of insulin resistance on platelet and vascular smooth muscle cell function. J Diabetes Complications 2002; 16: 35-40. – reference: Ogden CL, Yanovski SZ, Carroll MD, Flegal KM. The epidemiology of obesity. Gastroenterology 2007; 132: 2087-2102. – reference: Schneider DJ, Sobel BE. Synergistic augmentation of expression of plasminogen activator inhibitor type-1 induced by insulin, very-low-density lipoproteins, and fatty acids. Coron Artery Dis 1996; 7: 813-817. – reference: Samad F, Pandey M, Bell PA, Loskutoff DJ. Insulin continues to induce plasminogen activator inhibitor 1 gene expression in insulin-resistant mice and adipocytes. Mol Med 2000; 6: 680-692. – reference: Davi G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med 2007; 357: 2482-2494. – reference: Nakata M, Yada T, Soejima N, Maruyama I. Leptin promotes aggregation of human platelets via the long form of its receptor. Diabetes 1999; 48: 426-429. – reference: Dellas C, Schafer K, Rohm IK, Lankeit M, Leifheit M, Loskutoff DJ, Hasenfuss G, Konstantinides SV. Leptin signalling and leptin-mediated activation of human platelets: importance of JAK2 and the phospholipases Cgamma2 and A2. Thromb Haemost 2007; 98: 1063-1071. – reference: Chen B, Lam KS, Wang Y, Wu D, Lam MC, Shen J, Wong L, Hoo RL, Zhang J, Xu A. Hypoxia dysregulates the production of adiponectin and plasminogen activator inhibitor-1 independent of reactive oxygen species in adipocytes. Biochem Biophys Res Commun 2006; 341: 549-556. – reference: Van Der PD, Milner KL, Hui J, Hodge A, Trenell MI, Kench JG, London R, Peduto T, Chisholm DJ, George J. Visceral fat: a key mediator of steatohepatitis in metabolic liver disease. Hepatology 2008; 48: 449-457. – reference: Trovati M, Anfossi G, Cavalot F, Massucco P, Mularoni E, Emanuelli G. Insulin directly reduces platelet sensitivity to aggregating agents. Studies in vitro and in vivo. Diabetes 1988; 37: 780-786. – reference: Konstantinides S, Schafer K, Koschnick S, Loskutoff DJ. Leptin-dependent platelet aggregation and arterial thrombosis suggests a mechanism for atherothrombotic disease in obesity. J Clin Invest 2001; 108: 1533-1540. – reference: Zhou L, Sell H, Eckardt K, Yang Z, Eckel J. Conditioned medium obtained from in vitro differentiated adipocytes and resistin induce insulin resistance in human hepatocytes. FEBS Lett 2007; 581: 4303-4308. – reference: Napoleone E, Di Santo A, Amore C, Baccante G, Di Febbo C, Porreca E, De Gaetano G, Donati MB, Lorenzet R. Leptin induces tissue factor expression in human peripheral blood mononuclear cells: a possible link between obesity and cardiovascular risk? J Thromb Haemost 2007; 5: 1462-1468. – reference: Sawdey MS, Loskutoff DJ. Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-alpha, and transforming growth factor-beta. J Clin Invest 1991; 88: 1346-1353. – reference: Cancello R, Tordjman J, Poitou C, Guilhem G, Bouillot JL, Hugol D, Coussieu C, Basdevant A, Bar HA, Bedossa P, Guerre-Millo M, Clement K. Increased infiltration of macrophages in omental adipose tissue is associated with marked hepatic lesions in morbid human obesity. Diabetes 2006; 55: 1554-1561. – reference: Konstantinides S, Schafer K, Neels JG, Dellas C, Loskutoff DJ. Inhibition of endogenous leptin protects mice from arterial and venous thrombosis. Arterioscler Thromb Vasc Biol 2004; 24: 2196-2201. – reference: Clement S, Juge-Aubry C, Sgroi A, Conzelmann S, Pazienza V, Pittet-Cuenod B, Meier CA, Negro F. Monocyte chemoattractant protein-1 secreted by adipose tissue induces direct lipid accumulation in hepatocytes. Hepatology 2008; 48: 799-807. – reference: Bogdanov VY, Balasubramanian V, Hathcock J, Vele O, Lieb M, Nemerson Y. Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein. Nat Med 2003; 9: 458-462. – reference: Hori Y, Nakatani K, Morioka K, Katsuki A, Gabazza EC, Yano Y, Nobori T, Adachi Y, Sumida Y. Insulin enhanced thrombin-activable fibrinolysis inhibitor expression through PI3 kinase/Akt pathway. Int J Mol Med 2005; 15: 265-268. – reference: Cigolini M, Targher G, Agostino G, Tonoli M, Muggeo M, De SG. Liver steatosis and its relation to plasma haemostatic factors in apparently healthy men - role of the metabolic syndrome. Thromb Haemost 1996; 76: 69-73. – reference: Wallace AM, McMahon AD, Packard CJ, Kelly A, Shepherd J, Gaw A, Sattar N. Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS). Circulation 2001; 104: 3052-3056. – reference: Shoji T, Koyama H, Fukumoto S, Maeno T, Yokoyama H, Shinohara K, Emoto M, Shoji T, Yamane T, Hino M, Shioi A, Nishizawa Y. Platelet activation is associated with hypoadiponectinemia and carotid atherosclerosis. Atherosclerosis 2006; 188: 190-195. – reference: Fontana L, Eagon JC, Trujillo ME, Scherer PE, Klein S. Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. Diabetes 2007; 56: 1010-1013. – reference: Samad F, Pandey M, Loskutoff DJ. Regulation of tissue factor gene expression in obesity. Blood 2001; 98: 3353-3358. – reference: Santos-Martinez MJ, Medina C, Jurasz P, Radomski MW. Role of metalloproteinases in platelet function. Thromb Res 2008; 121: 535-542. – reference: Busam KJ, Bauer TM, Bauer J, Gerok W, Decker K. Interleukin-6 release by rat liver macrophages. J Hepatol 1990; 11: 367-373. – reference: Wang Z, Lv J, Zhang R, Zhu Y, Zhu D, Sun Y, Zhu J, Han X. Co-culture with fat cells induces cellular insulin resistance in primary hepatocytes. Biochem Biophys Res Commun 2006; 345: 976-983. – volume: 24 start-page: 2196 year: 2004 end-page: 2201 article-title: Inhibition of endogenous leptin protects mice from arterial and venous thrombosis publication-title: Arterioscler Thromb Vasc Biol – volume: 108 start-page: 1533 year: 2001 end-page: 1540 article-title: Leptin‐dependent platelet aggregation and arterial thrombosis suggests a mechanism for atherothrombotic disease in obesity publication-title: J Clin Invest – volume: 37 start-page: 780 year: 1988 end-page: 786 article-title: Insulin directly reduces platelet sensitivity to aggregating agents. Studies and publication-title: Diabetes – volume: 44 start-page: 139 year: 1991 end-page: 143 article-title: Distribution of plasminogen activator inhibitor (PAI‐1) in tissues publication-title: J Clin Pathol – volume: 7 start-page: 710 year: 2001 end-page: 712 article-title: Overexpression of hepatic plasminogen activator inhibitor type 1 mRNA in rabbits with fatty liver publication-title: World J Gastroenterol – volume: 41 start-page: 65 year: 1998 end-page: 71 article-title: Adipose tissue secretion of plasminogen activator inhibitor‐1 in non‐obese and obese individuals publication-title: Diabetologia – volume: 54 start-page: 220 year: 2005 end-page: 226 article-title: Insulin enhances vascular endothelial growth factor, interleukin‐8, and plasminogen activator inhibitor 1 but not interleukin‐6 release by human adipocytes publication-title: Metabolism – volume: 20 start-page: 1682 year: 2000 end-page: 1687 article-title: Role of cytokines in the regulation of plasminogen activator inhibitor‐1 expression and secretion in newly differentiated subcutaneous human adipocytes publication-title: Arterioscler Thromb Vasc Biol – volume: 121 start-page: 535 year: 2008 end-page: 542 article-title: Role of metalloproteinases in platelet function publication-title: Thromb Res – volume: 56 start-page: 1010 year: 2007 end-page: 1013 article-title: Visceral fat adipokine secretion is associated with systemic inflammation in obese humans publication-title: Diabetes – volume: 48 start-page: 799 year: 2008 end-page: 807 article-title: Monocyte chemoattractant protein‐1 secreted by adipose tissue induces direct lipid accumulation in hepatocytes publication-title: Hepatology – volume: 87 start-page: 660 year: 2002 end-page: 665 article-title: Insulin resistance is associated with increased circulating level of thrombin‐activatable fibrinolysis inhibitor in type 2 diabetic patients publication-title: J Clin Endocrinol Metab – volume: 76 start-page: 203 year: 1989 end-page: 208 article-title: Factor VII coagulant activity is strongly associated with the plasma concentration of large lipoprotein particles in middle‐aged men publication-title: Atherosclerosis – volume: 48 start-page: 426 year: 1999 end-page: 429 article-title: Leptin promotes aggregation of human platelets via the long form of its receptor publication-title: Diabetes – volume: 76 start-page: 69 year: 1996 end-page: 73 article-title: Liver steatosis and its relation to plasma haemostatic factors in apparently healthy men – role of the metabolic syndrome publication-title: Thromb Haemost – volume: 5 start-page: 1462 year: 2007 end-page: 1468 article-title: Leptin induces tissue factor expression in human peripheral blood mononuclear cells: a possible link between obesity and cardiovascular risk? publication-title: J Thromb Haemost – volume: 84 start-page: 216 year: 2000 end-page: 222 article-title: The factor VIII acute phase response requires the participation of NF‐kappa B and C/EBP publication-title: Thromb Haemost – volume: 99 start-page: 290 year: 2008 end-page: 294 article-title: Role of proteolysis in development of murine adipose tissue publication-title: Thromb Haemost – volume: 95 start-page: 7591 year: 1998 end-page: 7596 article-title: Tissue factor gene expression in the adipose tissues of obese mice publication-title: Proc Natl Acad Sci U S A – volume: 104 start-page: 3052 year: 2001 end-page: 3056 article-title: Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS) publication-title: Circulation – volume: 6 start-page: 1012 year: 2008 end-page: 1020 article-title: Globular adiponectin induces platelet activation through the collagen receptor GPVI‐Fc receptor gamma chain complex publication-title: J Thromb Haemost – volume: 345 start-page: 976 year: 2006 end-page: 983 article-title: Co‐culture with fat cells induces cellular insulin resistance in primary hepatocytes publication-title: Biochem Biophys Res Commun – volume: 11 start-page: 950 year: 2003 end-page: 956 article-title: Weight loss reduces tissue factor in morbidly obese patients publication-title: Obes Res – volume: 1 start-page: 791 year: 2003 end-page: 797 article-title: Weak and non‐independent association between plasma TAFI antigen levels and the insulin resistance syndrome publication-title: J Thromb Haemost – volume: 101 start-page: 4844 year: 2003 end-page: 4846 article-title: Identification of thrombin activatable fibrinolysis inhibitor (TAFI) in human platelets publication-title: Blood – volume: 269 start-page: 546 year: 1995 end-page: 549 article-title: Recombinant mouse OB protein: evidence for a peripheral signal linking adiposity and central neural networks publication-title: Science – volume: 18 start-page: 38 year: 1992 end-page: 42 article-title: Plasminogen activator inhibitor 1 and insulin levels in various insulin resistance states publication-title: Diabete Metab – volume: 73 start-page: 150 year: 2006 end-page: 157 article-title: Different metabolic correlations of thrombin‐activatable fibrinolysis inhibitor and plasminogen activator inhibitor‐1 in non‐obese type 2 diabetic patients publication-title: Diabetes Res Clin Pract – volume: 98 start-page: 1063 year: 2007 end-page: 1071 article-title: Leptin signalling and leptin‐mediated activation of human platelets: importance of JAK2 and the phospholipases Cgamma2 and A2 publication-title: Thromb Haemost – volume: 89 start-page: 601 year: 2003 end-page: 609 article-title: Fibrin(ogen) in cardiovascular disease: an update publication-title: Thromb Haemost – volume: 23 start-page: 1262 year: 2003 end-page: 1268 article-title: Plasma PAI‐1 levels are more strongly related to liver steatosis than to adipose tissue accumulation publication-title: Arterioscler Thromb Vasc Biol – volume: 455 start-page: 479 year: 2007 end-page: 492 article-title: Dysregulation of the expression and secretion of inflammation‐related adipokines by hypoxia in human adipocytes publication-title: Pflugers Arch – volume: 35 start-page: 178 year: 2003 end-page: 182 article-title: Differences in plasminogen activator inhibitor 1 in subcutaneous versus omental adipose tissue in non‐obese and obese subjects publication-title: Horm Metab Res – volume: 18 start-page: 1 year: 1998 end-page: 6 article-title: The adipocyte and hemostatic balance in obesity: studies of PAI‐1 publication-title: Arterioscler Thromb Vasc Biol – volume: 15 start-page: 265 year: 2005 end-page: 268 article-title: Insulin enhanced thrombin‐activable fibrinolysis inhibitor expression through PI3 kinase/Akt pathway publication-title: Int J Mol Med – volume: 558 start-page: 7 year: 2007 end-page: 13 article-title: Adiponectin, ghrelin, and leptin differentially influence human platelet and human vascular endothelial cell functions: implication in obesity‐associated cardiovascular diseases publication-title: Eur J Pharmacol – volume: 55 start-page: 952 year: 2006 end-page: 961 article-title: Insulin signaling in human visceral and subcutaneous adipose tissue publication-title: Diabetes – volume: 67 start-page: 92 year: 2002 end-page: 98 article-title: Matrix metalloproteinases and cellular fibrinolytic activity publication-title: Biochemistry (Mosc) – volume: 188 start-page: 190 year: 2006 end-page: 195 article-title: Platelet activation is associated with hypoadiponectinemia and carotid atherosclerosis publication-title: Atherosclerosis – volume: 20 start-page: 2511 year: 2000 end-page: 2518 article-title: Thrombin activatable fibrinolysis inhibitor and an antifibrinolytic pathway publication-title: Arterioscler Thromb Vasc Biol – volume: 26 start-page: 224 year: 2006 end-page: 230 article-title: Adiponectin acts as an endogenous antithrombotic factor publication-title: Arterioscler Thromb Vasc Biol – volume: 581 start-page: 4303 year: 2007 end-page: 4308 article-title: Conditioned medium obtained from differentiated adipocytes and resistin induce insulin resistance in human hepatocytes publication-title: FEBS Lett – volume: 11 start-page: 183 year: 2005 end-page: 190 article-title: Local and systemic insulin resistance resulting from hepatic activation of IKK‐beta and NF‐kappa B publication-title: Nat Med – volume: 168 start-page: 1678 year: 2008 end-page: 1683 article-title: Overweight, obesity, and the risk of recurrent venous thromboembolism publication-title: Arch Intern Med – volume: 96 start-page: 6902 year: 1999 end-page: 6907 article-title: Tumor necrosis factor alpha is a key component in the obesity‐linked elevation of plasminogen activator inhibitor 1 publication-title: Proc Natl Acad Sci U S A – volume: 165 start-page: 1053 year: 2000 end-page: 1058 article-title: Pro‐carboxypeptidase R is an acute phase protein in the mouse, whereas carboxypeptidase N is not publication-title: J Immunol – volume: 55 start-page: 202 year: 2006 end-page: 208 article-title: Effects of hyperglycemia and hyperinsulinemia on circulating tissue factor procoagulant activity and platelet CD40 ligand publication-title: Diabetes – volume: 56 start-page: 901 year: 2007 end-page: 911 article-title: Adipose tissue hypoxia in obesity and its impact on adipocytokine dysregulation publication-title: Diabetes – volume: 88 start-page: 1346 year: 1991 end-page: 1353 article-title: Regulation of murine type 1 plasminogen activator inhibitor gene expression . Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor‐alpha, and transforming growth factor‐beta publication-title: J Clin Invest – volume: 132 start-page: 2087 year: 2007 end-page: 2102 article-title: The epidemiology of obesity publication-title: Gastroenterology – volume: 55 start-page: 1554 year: 2006 end-page: 1561 article-title: Increased infiltration of macrophages in omental adipose tissue is associated with marked hepatic lesions in morbid human obesity publication-title: Diabetes – volume: 98 start-page: 3353 year: 2001 end-page: 3358 article-title: Regulation of tissue factor gene expression in obesity publication-title: Blood – volume: 357 start-page: 2482 year: 2007 end-page: 2494 article-title: Platelet activation and atherothrombosis publication-title: N Engl J Med – volume: 7 start-page: 813 year: 1996 end-page: 817 article-title: Synergistic augmentation of expression of plasminogen activator inhibitor type‐1 induced by insulin, very‐low‐density lipoproteins, and fatty acids publication-title: Coron Artery Dis – volume: 158 start-page: 2485 year: 1998 end-page: 2490 article-title: Effect of intensive glycemic control on fibrinogen, lipids, and lipoproteins: veterans affairs cooperative study in type II diabetes mellitus publication-title: Arch Intern Med – volume: 107 start-page: 973 year: 2003 end-page: 977 article-title: Role of risk factors in the modulation of tissue factor activity and blood thrombogenicity publication-title: Circulation – volume: 9 start-page: 458 year: 2003 end-page: 462 article-title: Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein publication-title: Nat Med – volume: 341 start-page: 549 year: 2006 end-page: 556 article-title: Hypoxia dysregulates the production of adiponectin and plasminogen activator inhibitor‐1 independent of reactive oxygen species in adipocytes publication-title: Biochem Biophys Res Commun – volume: 6 start-page: 1198 year: 2008 end-page: 1206 article-title: A functional role of gelatinase A in the development of nutritionally induced obesity in mice publication-title: J Thromb Haemost – volume: 116 start-page: 1793 year: 2006 end-page: 1801 article-title: Inflammation and insulin resistance publication-title: J Clin Invest – volume: 6 start-page: 680 year: 2000 end-page: 692 article-title: Insulin continues to induce plasminogen activator inhibitor 1 gene expression in insulin‐resistant mice and adipocytes publication-title: Mol Med – volume: 56 start-page: 804 year: 2007 end-page: 808 article-title: Globular adiponectin activates nuclear factor‐kappa B and activating protein‐1 and enhances angiotensin II‐induced proliferation in cardiac fibroblasts publication-title: Diabetes – volume: 92 start-page: 4352 year: 2007 end-page: 4358 article-title: Circulating tissue factor procoagulant activity and thrombin generation in patients with type 2 diabetes: effects of insulin and glucose publication-title: J Clin Endocrinol Metab – volume: 11 start-page: 367 year: 1990 end-page: 373 article-title: Interleukin‐6 release by rat liver macrophages publication-title: J Hepatol – volume: 16 start-page: 35 year: 2002 end-page: 40 article-title: Influence of insulin and of insulin resistance on platelet and vascular smooth muscle cell function publication-title: J Diabetes Complications – volume: 49 start-page: 744 year: 2006 end-page: 747 article-title: Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin publication-title: Diabetologia – volume: 48 start-page: 449 year: 2008 end-page: 457 article-title: Visceral fat: a key mediator of steatohepatitis in metabolic liver disease publication-title: Hepatology – volume: 366 start-page: 1640 year: 2005 end-page: 1649 article-title: Obesity and the risk of myocardial infarction in 27 000 participants from 52 countries: a case–control study publication-title: Lancet – volume: 14 start-page: 16S issue: 1 year: 2006 end-page: 19S article-title: Why visceral fat is bad: mechanisms of the metabolic syndrome publication-title: Obesity (Silver Spring) – volume: 97 start-page: 37 year: 1996 end-page: 46 article-title: Distribution and regulation of plasminogen activator inhibitor‐1 in murine adipose tissue . Induction by tumor necrosis factor‐alpha and lipopolysaccharide publication-title: J Clin Invest – ident: e_1_2_9_47_2 doi: 10.1161/01.ATV.20.6.1682 – ident: e_1_2_9_59_2 doi: 10.1016/j.thromres.2007.06.002 – volume: 84 start-page: 216 year: 2000 ident: e_1_2_9_31_2 article-title: The factor VIII acute phase response requires the participation of NF‐kappa B and C/EBP publication-title: Thromb Haemost doi: 10.1055/s-0037-1613999 – ident: e_1_2_9_51_2 doi: 10.1161/01.ATV.20.12.2511 – ident: e_1_2_9_32_2 doi: 10.1016/0021-9150(89)90104-4 – ident: e_1_2_9_25_2 doi: 10.1161/01.CIR.0000050621.67499.7D – ident: e_1_2_9_43_2 doi: 10.1016/j.metabol.2004.08.016 – ident: e_1_2_9_39_2 doi: 10.1055/s-2003-39078 – ident: e_1_2_9_50_2 doi: 10.1007/s00424-007-0301-8 – ident: e_1_2_9_67_2 doi: 10.1038/oby.2006.277 – ident: e_1_2_9_3_2 doi: 10.1172/JCI29069 – ident: e_1_2_9_66_2 doi: 10.1002/hep.22350 – ident: e_1_2_9_7_2 doi: 10.1126/science.7624778 – ident: e_1_2_9_44_2 doi: 10.2337/diabetes.55.04.06.db05-1414 – ident: e_1_2_9_49_2 doi: 10.1016/j.bbrc.2006.01.004 – ident: e_1_2_9_62_2 doi: 10.1038/nm1166 – ident: e_1_2_9_36_2 doi: 10.1097/00019501-199611000-00004 – ident: e_1_2_9_34_2 doi: 10.1172/JCI118404 – ident: e_1_2_9_18_2 doi: 10.2337/diabetes.37.6.780 – ident: e_1_2_9_65_2 doi: 10.1016/j.febslet.2007.07.076 – ident: e_1_2_9_4_2 doi: 10.2337/db06-1656 – ident: e_1_2_9_29_2 doi: 10.1055/s-0037-1613566 – volume: 18 start-page: 38 year: 1992 ident: e_1_2_9_37_2 article-title: Plasminogen activator inhibitor 1 and insulin levels in various insulin resistance states publication-title: Diabete Metab – ident: e_1_2_9_5_2 doi: 10.1001/archinte.168.15.1678 – ident: e_1_2_9_27_2 doi: 10.1210/jc.2007-0933 – ident: e_1_2_9_45_2 doi: 10.1161/01.ATV.18.1.1 – ident: e_1_2_9_48_2 doi: 10.2337/db06-0911 – ident: e_1_2_9_14_2 doi: 10.1016/j.atherosclerosis.2005.10.034 – volume: 15 start-page: 265 year: 2005 ident: e_1_2_9_54_2 article-title: Insulin enhanced thrombin‐activable fibrinolysis inhibitor expression through PI3 kinase/Akt pathway publication-title: Int J Mol Med – ident: e_1_2_9_58_2 doi: 10.1023/A:1013908332232 – ident: e_1_2_9_24_2 doi: 10.1038/oby.2003.131 – ident: e_1_2_9_19_2 doi: 10.1016/S1056-8727(01)00196-9 – ident: e_1_2_9_2_2 doi: 10.1053/j.gastro.2007.03.052 – ident: e_1_2_9_41_2 doi: 10.1007/s00125-006-0173-z – ident: e_1_2_9_23_2 doi: 10.1182/blood.V98.12.3353 – volume: 99 start-page: 290 year: 2008 ident: e_1_2_9_57_2 article-title: Role of proteolysis in development of murine adipose tissue publication-title: Thromb Haemost doi: 10.1160/TH07-10-0589 – ident: e_1_2_9_26_2 doi: 10.2337/diabetes.55.01.06.db05-1026 – ident: e_1_2_9_16_2 doi: 10.1111/j.1538-7836.2008.02982.x – ident: e_1_2_9_60_2 doi: 10.1111/j.1538-7836.2008.02988.x – ident: e_1_2_9_35_2 doi: 10.1172/JCI115440 – ident: e_1_2_9_21_2 doi: 10.1073/pnas.95.13.7591 – ident: e_1_2_9_56_2 doi: 10.4049/jimmunol.165.2.1053 – ident: e_1_2_9_22_2 doi: 10.1038/nm841 – ident: e_1_2_9_61_2 doi: 10.1016/0168-8278(90)90223-E – ident: e_1_2_9_42_2 doi: 10.1007/BF03402048 – ident: e_1_2_9_13_2 doi: 10.1161/01.ATV.0000194076.84568.81 – ident: e_1_2_9_33_2 doi: 10.1136/jcp.44.2.139 – ident: e_1_2_9_6_2 doi: 10.1016/S0140-6736(05)67663-5 – ident: e_1_2_9_15_2 doi: 10.1016/j.ejphar.2006.11.052 – ident: e_1_2_9_63_2 doi: 10.2337/db06-0133 – ident: e_1_2_9_53_2 doi: 10.1182/blood-2002-09-2944 – ident: e_1_2_9_46_2 doi: 10.1073/pnas.96.12.6902 – ident: e_1_2_9_9_2 doi: 10.1172/JCI13143 – ident: e_1_2_9_28_2 doi: 10.1111/j.1538-7836.2007.02578.x – ident: e_1_2_9_12_2 doi: 10.1160/TH07-03-0213 – ident: e_1_2_9_64_2 doi: 10.1016/j.bbrc.2006.04.173 – ident: e_1_2_9_69_2 doi: 10.3748/wjg.v7.i5.710 – ident: e_1_2_9_10_2 doi: 10.1161/01.ATV.0000146531.79402.9a – ident: e_1_2_9_17_2 doi: 10.2337/db06-1405 – ident: e_1_2_9_20_2 doi: 10.1056/NEJMra071014 – ident: e_1_2_9_8_2 doi: 10.1161/hc5001.101061 – ident: e_1_2_9_40_2 doi: 10.1016/j.diabres.2005.12.008 – ident: e_1_2_9_52_2 doi: 10.1210/jcem.87.2.8214 – ident: e_1_2_9_11_2 doi: 10.2337/diabetes.48.2.426 – ident: e_1_2_9_30_2 doi: 10.1001/archinte.158.22.2485 – ident: e_1_2_9_68_2 doi: 10.1002/hep.22404 – ident: e_1_2_9_55_2 doi: 10.1046/j.1538-7836.2003.00147.x – ident: e_1_2_9_71_2 doi: 10.1161/01.ATV.0000077401.36885.BB – ident: e_1_2_9_38_2 doi: 10.1007/s001250050868 – volume: 76 start-page: 69 year: 1996 ident: e_1_2_9_70_2 article-title: Liver steatosis and its relation to plasma haemostatic factors in apparently healthy men – role of the metabolic syndrome publication-title: Thromb Haemost doi: 10.1055/s-0038-1650524 |
| SSID | ssj0017931 |
| Score | 2.3517954 |
| SecondaryResourceType | review_article |
| Snippet | Obesity is associated with an increased incidence of insulin resistance (IR), type 2 diabetes mellitus and cardiovascular diseases. The increased risk for... Summary Obesity is associated with an increased incidence of insulin resistance (IR), type 2 diabetes mellitus and cardiovascular diseases. The increased risk... SummaryObesity is associated with an increased incidence of insulin resistance (IR), type 2 diabetes mellitus and cardiovascular diseases. The increased risk... |
| SourceID | proquest pubmed crossref wiley istex fao |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 554 |
| SubjectTerms | adiponectin Adipose tissue Adipose Tissue - physiology Animals blood platelets Blood Platelets - physiology cardiovascular diseases coagulation factor VII factor VIII fibrinogen fibrinolysis Fibrinolysis - physiology free fatty acids haemostasis hemostasis Humans inflammation insulin resistance interleukin-1beta interleukin-6 leptin Liver Liver - physiology neoplasms noninsulin-dependent diabetes mellitus obesity physiology plasminogen activator inhibitors risk tumor necrosis factor-alpha |
| Title | Role of adipose tissue in haemostasis, coagulation and fibrinolysis |
| URI | https://api.istex.fr/ark:/67375/WNG-S6TFT78X-4/fulltext.pdf https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fj.1467-789X.2009.00593.x https://www.ncbi.nlm.nih.gov/pubmed/19460118 https://www.proquest.com/docview/21071469 https://www.proquest.com/docview/46379746 https://www.proquest.com/docview/734020154 |
| Volume | 10 |
| WOSCitedRecordID | wos000269387400005&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVWIB databaseName: Wiley Online Library customDbUrl: eissn: 1467-789X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017931 issn: 1467-7881 databaseCode: DRFUL dateStart: 20000101 isFulltext: true titleUrlDefault: https://onlinelibrary.wiley.com providerName: Wiley-Blackwell |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwEB7RLUJceNOGR_EBcSIoiePXsS0sHGBB212Rm-XEdlm1JNWmRf35jJPsohWtVCFuPtiOPJ4Zf5N5AbzOhFHSlDbOc5PFuahsXEqh4hRfIyucKBPWN5sQk4ksCvVtiH8KuTB9fYj1D7cgGZ2-DgJuyvZvIRdSFauyk0zRd4gntzNkYzaC7ffT8fzz2qeAnJj2uUZhlUw343qu3GvjsdrypkEIG6h_eRUe3YS33fs0vv8_T_YA7g0olez3bPUQbrn6Edz5MvjhH8PhtDl1pPHE2MVZ0zpy3t0fWdTkh3E_G4Sc7aJ9S6rGHA_9wYipLfEhwaBuujIoT2A-_jA7_BQP7RjiijFBY1oqV3KacotKyTNXUea9TajhzjmVWJFZJ7jLnJWcS5mnuReZt2iQcONDHbqnMKqb2u0CQTWByFL5xBmelzi2zNuKZaWlNEuqNAKxoruuhlrloWXGqd6wWYQONAqdNJXuaKQvI0jXK8_6eh03WLOLV6vNMapVPT_KgjM35WjnShnBm-6-13uZ5UkIhRNMf5981Ed8Np4JWeg8glcrhtAooMHrYmrXXLQabWqB31XXz8g5FWjW8QjINTMEDWY-ot0Idnpm-3M4lfOQPRwB63jqxqfWXw-mOHj2j-uew93esRbC7V7A6Hx54V7C7eoXMtxyD7ZEIfcGCfwNKzkpog |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LbxMxEB5Bi6AXnn0sr_qAOLHVPvw8QiEUkQaUJiI3y7u2S9R2t0pa1J_PeHcTFNFKFeLmg8crj78Zz-x4ZgDeZMIoaQobU2qymIrSxoUUKk7xNrLCiSJhbbMJMRjIyUR979oBhVyYtj7E8odbkIxGXwcBDz-k_5ZyIdVkUXeSqXwPDcp1iqhCuK9_HPbG_WVQAaGYtslGgUqmqw97rl1r5ba6602NNmxg_9V1BumqfdtcUL1H_3Vrj-FhZ6eS9y2wnsAdVz2F-4ddJP4Z7A_rU0dqT4ydntdzRy6aEyTTivw07qxGo3M-nb8jZW2Ouw5hxFSW-JBiUNVNIZRNGPc-jfYP4q4hQ1wyJvI4L5QreJ5yi2rJM1fmzHub5IY751RiRWad4C5zVnIuJU2pF5m36JJw40Mlui1Yq-rK7QBBRYG2pfKJM5wWOLbM25Jlhc3zLCnTCMSC8brsqpWHphmnesVrETrwKPTSVLrhkb6KIF1SnrcVO25Bs4Nnq80xKlY9PspCODfl6OlKGcHb5sCXa5nZSXgMJ5j-Mfisj_ioNxJyomkEuwtEaBTREHcxlasv5xq9aoHfVTfPQLwKdOx4BOSGGSIPjj7auxFst2j7szlFecgfjoA1oLr1rvW3D0McPP9Hul14cDA67Ov-l8HXF7DRhtnC47uXsHYxu3Sv4F75C8E3e90J4m8KpSyq |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwEB7BFlVceJeGV31AnAjKw88jtAQQZam2u2JvlhPbZUVJVrst6s9nnGQXrWilCnHzwePI45nxNxnPDMDLTBglTWljSk0WU1HZuJRCxSneRlY4USasazYhhkM5naqjvh1QyIXp6kOsf7gFzWjtdVBwN7f-by0XUk1XdSeZyt8goNyioafMALYORsXkcB1UQFFMu2SjQCXTzYc9l661cVvd9KZBDBvYf3EZIN3Et-0FVdz9r1u7B3d6nEredoJ1H264-gFsf-kj8Q9hf9ScOtJ4Yuxs3iwdOWtPkMxq8t24nw2CzuVs-ZpUjTnpO4QRU1viQ4pB3bSFUB7BpHg_3v8Y9w0Z4ooxkcd5qVzJ85RbNEueuSpn3tskN9w5pxIrMusEd5mzknMpaUq9yLxFl4QbHyrR7cCgbmq3CwQNBWJL5RNnOC1xbJm3FctKm-dZUqURiBXjddVXKw9NM071htcidOBR6KWpdMsjfRFBuqacdxU7rkGzi2erzQkaVj05zkI4N-Xo6UoZwav2wNdrmcWP8BhOMP1t-EEf83ExFnKqaQR7K4nQqKIh7mJq15wvNXrVAr-rrp5BeS7QseMRkCtmiDw4-oh3I3jcSdufzSnKQ_5wBKwVqmvvWn99N8LBk3-k24Pto4NCH34afn4Kt7soW3h79wwGZ4tz9xxuVb9Q9hYvej38DVCoLCU |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Role+of+adipose+tissue+in+haemostasis%2C+coagulation+and+fibrinolysis&rft.jtitle=Obesity+reviews&rft.au=Faber%2C+D.+R.&rft.au=De+Groot%2C+Ph.+G.&rft.au=Visseren%2C+F.+L.+J.&rft.date=2009-09-01&rft.pub=Blackwell+Publishing+Ltd&rft.issn=1467-7881&rft.eissn=1467-789X&rft.volume=10&rft.issue=5&rft.spage=554&rft.epage=563&rft_id=info:doi/10.1111%2Fj.1467-789X.2009.00593.x&rft.externalDBID=n%2Fa&rft.externalDocID=ark_67375_WNG_S6TFT78X_4 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1467-7881&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1467-7881&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1467-7881&client=summon |